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KEY INSIGHTS 
1. A Fully Managed HomeCare and Home Delivery 
model provides better financial returns than 
either an Outsourced or traditional distribution 
model.   
2. Both the Fully Managed and Outsourced 
HomeCare and Home Delivery models 
significantly improve days of inventory over the 
As-Is situation. 
3. The Netherlands is the ideal market for 
manufacturers to develop an innovative 
distribution model; the market can also act as a 
staging ground for other European markets. 
Introduction 
As people age, their need for medical attention 
increases, and mobility becomes a more challenging 
issue. Although people over 60 currently represent 
between 12 to 18% of the total population in 
developed countries, they consume about half of all 
prescription medicines, which is equivalent to almost 
three times that of someone in the general population 
(Sabaté, 2003).  In Europe, the population will 
increasingly shift towards this older demographic as 
36 M more people will join those aged over 65 in the 
next 20 years, which will make up 23.6% of the total 
population in 2030 (Konstantinos, 2010).   
 
Governments in Europe are also experiencing a time 
of austerity, and as the stakeholder who has to pay 
the lion’s share of the final medical bill, there is huge 
irreversible pressure to contain drug costs while 
improving public access to medicines.  The greatest 
impact of these changes will be borne by the 
pharmaceutical industry, which will need to adapt to 
the changing economics of the business.  
Pharmaceutical manufacturers have traditionally 
relied on R&D and marketing to churn out innovative 
products.  However, as future cash flows increasingly 
shrink from not only governmental regulation but also 
from the rise of generic competition, a products-only 
view will limit the long term viability of many 
operations.  
In response to these challenges, innovations and 
improvements in the pharmaceutical supply chain 
can help stem the tide for manufacturers and open 
up new markets and opportunities.  Distribution 
models such as Direct to Pharmacy and Direct to 
Hospital are already gaining a foothold in many 
markets as manufacturers try to circumvent 
wholesalers and the traditional supply chain.  In this 
analysis, however, the emphasis is more on service-
oriented models where pharmaceutical companies 
can make an impact directly on the end consumer.  
Two of these models are Home Delivery and 
HomeCare, and while these concepts are not new in 
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the general sense, for the majority of pharmaceutical 
manufacturers, they represent greenfield 
opportunities and a chance to truly respond to the 
changing needs of healthcare. 
HomeCare & Home Delivery 
Currently, 74% of all pharmaceuticals are distributed 
through wholesalers in Europe; on top of the 
governmental pressures manufacturers face, 
wholesalers and pharmacies are consolidating to 
further squeeze margins (Bünte et al., 2007).  The 
practice of delivering drugs and/or services directly 
to the home, called Home Delivery and HomeCare, 
respectively, may be a way for manufacturers to 
gain some control and visibility in the value chain. 
Standalone mail-order / Internet pharmacies are 
already quite popular, and well-established 
HomeCare companies from the UK and the 
Netherlands are expanding their reach in continental 
Europe.  A further description of these models 
follows: 
 Home Delivery HomeCare 
Key Value 
Proposition 
- Lower cost to 
payors and patients 
- Patient focused 
care 
Other 
benefits 
- Better availability 
and access to 
medication for 
patients 
- Alleviates strain on 
the hospital system 
- Often lower costs 
to the payor vs. 
hospital care 
Common 
Benefits 
- Improved patient compliance 
- Increased privacy 
- Convenience for the patient  
  (e.g., reduced patient travel time) 
Key Hurdles - Widespread 
regulation 
prohibiting sale and 
distribution of 
prescription by mail 
order 
- Assured 
resistance from 
wholesaler and 
pharmacy 
associations 
- Gaining 
acceptance and 
approval from 
physicians and 
patients 
- Ensuring cost 
savings can be 
achieved versus 
traditional hospital 
care 
 
To address the feasibility and potential for a 
pharmaceutical manufacturer to start a Home 
Delivery and/or a HomeCare business, the 
questions Where? and How? need to be answered. 
For this purpose, a simulation model was developed 
to more finely evaluate the economic potential for a 
particular basket of drugs in specific markets. 
Ideal Potential and Feasible Markets 
A prioritization process was designed taking two 
main dimensions into consideration: potential and 
feasibility. Potential is defined as the opportunity of 
capturing new business through the implementation 
of novel business models given the characteristics of 
a certain market, such as the pharmaceutical 
market, income per capita, demographic profile, and 
the amount of public medical coverage. 
Feasibility, on the other hand, is related to the 
likelihood for a certain model to be successful, 
considering the development and restrictions 
imposed by regulations and the political 
environment, logistical and healthcare infrastructure, 
and urban density. 
The results of this process yielded five top countries 
that scored well on both dimensions.  Further 
importance given to the market environments 
narrowed the choice countries to Germany, 
Switzerland, and The Netherlands. 
Three Scenarios 
From a further in-depth study of the selected 
countries, including their current pharmaceutical 
distribution, market forces and regulatory 
requirements, two different alternatives for the 
implementation of a Home Delivery and HomeCare 
model to deliver goods from manufacturers directly 
to patients were introduced. A baseline was also 
established to benchmark the performance of the 
designed scenarios.  Performance was evaluated 
from both a financial and operational perspective 
1) Base Model (As-Is Scenario) 
The base model is built on the dominant “As-Is” 
situation of the traditional pharmaceutical supply 
chain.  Goods and their ownership will transfer 
through the manufacturer to the wholesaler to the 
pharmacies and then finally to the patient. Other key 
stakeholders where information and funds are 
transferred include the insurance funds, doctors and 
the pre-wholesalers with the latter usually operating 
as an LSP for the manufacturer.  
2) Fully Managed Supply Chain (FMSC) Scenario 
In FMSC, the manufacturers keep ownership of the 
inventory until it is shipped directly to the patients. 
Depending on the product classification and 
customer requirements, the package provided could 
range from a basic home delivery of product with no 
additional services to a comprehensive HomeCare 
scheme encompassing product delivery, nursing, 
follow up on care plan, and so on. 
In this scenario, a third-party company, such as a 
HomeCare specialized service provider or a logistics 
operator, would provide services related with the 
actual pick-up and delivery of goods and support 
services, administration of patients information, 
scheduling of appointments, provision of pre- and 
post-sales support and assistance in the accounts 
receivable process by collecting payment, among 
others.   
 
3) Outsourced Supply Chain (OSC) Scenario 
In OSC, the ownership of inventory is transferred 
from the producer to the third-party.  In addition to 
the functions performed in the “fully managed supply 
chain” scenario, the third-party will be the holder and 
owner of inventory at their locations. Manufacturers 
would no longer be involved in invoicing final 
customers or in the reimbursement processes, which 
now would be the responsibility of the third-party. 
Different from a wholesaler role, the third-party 
would act as an intermediary, adding value to the 
product by encompassing it in Home Delivery or 
HomeCare services to patients. 
 
 
 
Six Products 
The pharmaceutical products selected for the 
simulation were mainly based on whether they treat 
an age-related disease or not, as these would 
represent ideal products for either Home Delivery or 
HomeCare.  The government generally fixes 
margins, and so the products also needed to have a 
high ex-factory price to be able to warrant adding the 
additional services provided by HomeCare and 
Home Delivery. In addition, a representation of 
drugs with different product attributes were sought 
after that would be used as the basis for segmenting 
whether the drug would be more suitable for Home 
Delivery or Home Care.  For instance, a drug that 
requires the assistance of another person to 
administer (e.g., drugs that are delivered by IV) 
would be weighted more towards HomeCare. 
The final basket of six drugs was narrowed down by  
the availability of historic sales data.  Drugs that 
treated cardiovascular (CARD), musculoskeletal 
(MUSC), nervous system (NERV), and blood 
disorder (BLOD) diseases as well as cancer (CANC) 
and erectile dysfunction (ED) were ultimately 
selected. The selected NERV drug is not 
commercialized in The Netherlands. 
Simulation Results 
Overall, the proposed models improve the financial 
performance for the manufacturer, increasing its 
operational profits compared to the base scenario. 
For the FMSC scenario, all products generate 
incremental margins over the base case, ranging 
from a low of 6.9% for CARD in Germany to 35.5% 
for BLOD in Switzerland.  Higher margin 
improvement is mainly associated with two factors: 
channel margin captured and distribution model 
used (either HomeCare or Home Delivery), due to 
the product’s attributes.  
The OSC scenario generates lower profits in all 
cases, considering the benefit is now split between 
the manufacturer and a third party, which in this 
case, is a HomeCare provider.  Because the 
HomeCare provider takes ownership of the inventory 
and handles the day-to-day operations, they can 
justifiably capture more of the overall margin from 
the manufacturer.  
Operational areas like inventory management are 
also improved because of the reduction of the 
“bullwhip” effect generated by intermediaries, which 
translates into lower average days of inventory, 
between 10 and 25 days for all scenarios. 
Strong linear relationships were detected between 
varying market capture, upsides and the final price 
with the profit increase/decrease. As far as the 
upsides are concerned, the FMSC model generates 
average incremental profit in the three years 
simulated for all products and countries analyzed in 
the realistic range of 4-11% upsides captured 
(Bates, 2008). The OSC model is more sensitive to 
upsides as a few products become unprofitable 
when upsides are in the lower end of the range.  
The analysis of the impact on profits at different 
levels of market capture shows that small changes 
in the latter generate a significant effect on the 
former. This is valid for all three countries under both 
scenarios.  In the FMSC scenario, an increase of 2% 
in market capture changes the incremental profits in 
approximately 24%, while for the OSC model the 
change is around 20%. With such a large impact, it 
is clear that successful implementation of the model 
will be driven by the ability of the manufacturers to 
shift demand from the traditional channels to the 
new proposals and will require significant effort and 
investment.  Another outcome is the fact that a 
minimum threshold between 8-10% market capture 
is necessary to achieve a break-even point, varying 
from country to country and between products and 
both scenarios. 
In either scenario, operational profits are highest for 
The Netherlands for the total basket of drugs.  The 
same is true when full business cases are prepared 
and upfront investments of IT and other overhead 
are factored into a Discounted Cash Flow Analysis. 
Conclusions 
The analysis shows that it is feasible for a 
manufacturer to initiate a HomeCare and Home 
Delivery channel in The Netherlands.  Good 
economics, however, are only a small part of the 
equation to determine whether these models will be 
successful.  Regulatory issues and powerful 
stakeholders could still block the way for any 
implementation.  The key, therefore, is to present a 
business not as a means of capturing more margins 
but offering a cost-effective solution to meet the ever 
growing healthcare needs.   
Because The Netherlands has a liberal regulatory 
environment and some of the fewest restrictions for 
pharmaceutical distribution in all of Europe, a 
partnership with another powerful stakeholder could 
guarantee improved market access.  The most 
important takeaway is to have an ally in the value 
chain to signal that the manufacturer is truly 
interested in improving the state of healthcare as a 
whole.  In addition, since the manufacturers have 
little experience dealing with patients directly, a good 
intermediary that has been able to focus on patient 
customer service may be a key missing link.    
The Netherlands would be an important stepping-
stone in subsequently opening other operations in 
other countries (such as Switzerland and Germany) 
and having a wider international presence.  It is 
possible to operate and manage across borders in 
the EU, and frequently the most stringent 
requirement is that the drugs themselves are 
originated locally.  
HomeCare and Home Delivery are two important 
models that will enable governments, sick funds and 
citizens to decrease healthcare costs.  Several 
manufacturers already operate these two models and 
have moved beyond simply selling products to 
offering complete healthcare solutions.  The 
pharmaceutical industry can broaden its role and 
help to successfully improve the lives of patients 
afflicted with chronic diseases or elderly people who 
live at home alone.  Facing a daunting challenge like 
aging baby boomers, pharmaceutical companies can 
leverage their resources and ability to play a central 
role in coordinating all of the stakeholders.  This 
shared urgency can ensure a sustainable healthcare 
system for the future. 
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